Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon

• Status: Completed
• Trial end date: 2020-01-16
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome

• Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician

• Patients using or willing to use the BETACONNECT autoinjector for Betaferon application

• Written informed consent

Exclusion Criteria:

• Patients receiving any other disease modifying drug

• Contraindications of Betaferon described in the Summary of Product Characteristics

• Patients participating in any other clinical or non-interventional study, evaluating MS therapy